*Refresh the page if the below document does not appear.
Wockhardt to sell domestic business as a part of major rearrangement
Mumbai-based Wockhardt pharma is planning to sell whole of its domestic business in a deal worth ₹2,000 Crore as a part of major rearrangement. Some sources informed that major pharma companies like Cipla and Dr. Reddy’s may consider buying the assets.
Glenmark launches new combination drug for Type-2 Diabetes
Glenmark Pharmaceuticals is the first company to launch a fixed-dose combination of teneligliptin (20mg) and dapagliflozin (5 mg or 10mg, respectively). The combination drug named Zeta-D is to be sold on the prescription of a registered medical practitioner only and is indicated to treat Type-2 diabetes in adults.
Lupin plans to acquire two inhalation brands from Sunovion for 75 Million USD
On Thursday, Lupin Pharmaceuticals announced that it is going to acquire two inhalation brands (Brovana and Xopenex HFA) from Sunovion Pharmaceuticals for 75 million USD. This acquisition will help Lupin expand its respiratory drug product portfolio in the US and strengthen its presence in respiratory therapeutics area.
USFDA issues form 483 with 17 observations to Lupin Pharma
Earlier this month, the US regulatory body conducted a pre-approved inspection at Lupin’s biotech manufacturing unit in Pune following which it issued a form 483 with 17 observations. The company does not think that there will be any fall in the revenue for this facility following the issuance of observations.
GSK's Shingrix vaccine shows positive results against shingles in adults
GSK Pharmaceuticals announced positive results regarding the ZOSTER-049 extension study showing that Shingrix (zoster vaccine recombinant, adjuvanted) with an initial vaccination can provide a minimum of a decade of immunity against Herpes Zoster virus which is responsible for shingles in adults.
First Cancer voluntary licensing agreement a big entry in Global Patent arena
To provide access to essential medicines to people belonging from middle and low-income countries, the global patent pool signed a first of its kind voluntary licensing agreement for a Cancer treatment, Novartis AG’s Tasigna named “nilotinib” .
CDSCO panel gives conditional approval for Nimesulide granules
The SEC under CDSCO has approved Dr. Reddy’s
laboratories to manufacture and market
Nimesulide granules for Oral Suspension (100
mg) indicated for the treatment of short-term
inflammatory conditions. The only condition
being it should be made available only on the
prescription of a registered physician.
